Compared to the current available treatments, it is a great improvement in treatments as the expected GBM patient survival of CAR-T treatments is over 30 percent (Ostrom et al., 2018) There are clinical trials regaring both mTOR and HER2 targeting CAR-T cells (NCT02208362 and NCT02442297 respectively) and it is aimed to introduce commercially available CAR-T immunotherapies for GBM patients while also trying to overcome some challenges of CAR-T cells (described later in this review). This evidence concerns the gene MTOR and glioblastoma.